• AngioDynamics, Inc. (NASDAQ:ANGO) reported a narrower-than-expected Q1 fiscal 2026 loss per share of $0.10, beating the Zacks Consensus Estimate.
• The company's revenue reached $75.71 million, marking a 12.2% year-over-year increase, driven by significant growth in its Med Tech segment.
• AngioDynamics raised its fiscal year 2026 sales outlook to $308 million to $313 million, reflecting confidence in continued growth.

AngioDynamics, Inc. (NASDAQ:ANGO), a prominent figure in the medical technology industry, focuses on improving vascular blood flow and expanding cancer treatment options. The company's recent first-quarter fiscal 2026 earnings showcased a narrower-than-expected loss per share of $0.10, surpassing the Zacks Consensus Estimate of a $0.14 loss. This performance indicates an improvement from the previous year's adjusted loss of $0.11 per share.

ANGO's revenue for the quarter was $75.71 million, slightly below the estimated $75.94 million but still represents a 12.2% increase from the previous year. This growth was significantly propelled by a 26.1% increase in its Med Tech segment. Following these results, AngioDynamics' CEO, Jim Clemmer, announced an upward revision of the fiscal year 2026 sales outlook to a range of $308 million to $313 million.

The company's pro-forma adjusted figures, excluding the impact of divested businesses and discontinued products, revealed a GAAP loss per share of $0.26, an improvement from the previous year's loss of $0.32. Despite a negative price-to-earnings (P/E) ratio of -14.44, AngioDynamics maintains a strong liquidity position with a current ratio of 2.29, indicating it has more than twice the amount of current assets compared to its current liabilities.

Following the earnings report, AngioDynamics' stock experienced a significant surge of 10.5% by 11:25 a.m. ET, reflecting investor confidence in the company's performance and future prospects. The company's gross profit margin increased to 55.3%, 90 basis points higher than the previous year, although the GAAP-calculated earnings were lower than the $0.10 per-share adjusted profit.

Despite financial ratio challenges, such as a price-to-sales ratio of 1.53 and an enterprise value to operating cash flow ratio of -49.91, AngioDynamics continues to focus on its core operations. The company's ongoing efforts to improve patient quality of life and expand its medical technology offerings are key drivers of its current momentum and future growth potential.